16 results
DEFM14A
SQZB
SQZ Biotechnologies Co
23 Jan 24
Proxy related to merger
4:31pm
cell, immunology, cancer, regenerative medicine, and cellular therapy research. STEMCELL Parent’s principal executive office is located at 1618 … scientists in the immunology and regenerative medicine fields, the team discovered the process’ novel capabilities and potential for significant impact through
PREM14A
SQZB
SQZ Biotechnologies Co
12 Jan 24
Preliminary proxy related to merger
8:57am
the world working on stem cell, immunology, cancer, regenerative medicine, and cellular therapy research. STEMCELL Parent’s principal executive office … collaboration with leading scientists in the immunology and regenerative medicine fields, the team discovered the process’ novel capabilities and potential
8-K
EX-99.3
SQZB
SQZ Biotechnologies Co
9 Dec 21
Other Events
7:30am
Autoimmune Infectious Disease Regenerative Medicine SQZ™ Technology Potentially enables engineering of many previously challenging biologies Robust process
8-K
EX-99.2
SQZB
SQZ Biotechnologies Co
13 Sep 21
SQZ Biotechnologies Announces First Autoimmune Disease Indication
6:53am
++ +++ and reliability Almost all cell therapies today are produced with Regenerative electroporation or viral transduction techniques Medicine 6
Directing
8-K
EX-99.2
b9aa1l1jv21pg2nbat34
4 Jun 21
Regulation FD Disclosure
8:09am
10-K
6t5o1gqu
18 Mar 21
Annual report
6:31am
424B4
ipqqdbje0lst5tsme5p
12 Feb 21
Prospectus supplement with pricing info
5:10pm
DRS
hxq rl9agt
1 Feb 21
Draft registration statement
12:00am
424B4
bimxr
30 Oct 20
Prospectus supplement with pricing info
4:54pm
S-1
msc335zblz 34
9 Oct 20
IPO registration
4:59pm
DRS/A
sadm0 iqomufad2
25 Sep 20
Draft registration statement (amended)
12:00am
DRS/A
7bzcdaodsv95 0ga
28 Aug 20
Draft registration statement (amended)
12:00am
DRS
ww6qn
21 Jul 20
Draft registration statement
12:00am
- Prev
- 1
- Next